Increased circulating CC chemokine levels in the metabolic syndrome are reduced by low-dose atorvastatin treatment: Evidence from a randomized controlled trial

Clinical Endocrinology

Volumn 79, Issue 6, 2013, Pages 800-806

  Loughrey, Brona V ^a   McGinty, Ann ^b   Young, Ian S ^b   McCance, David R ^a   Powell, Lesley A ^b  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BETA CHEMOKINE; C REACTIVE PROTEIN; CD14 ANTIGEN; CHEMOKINE RECEPTOR CCR5; EOTAXIN; EOTAXIN 2; FRACTALKINE; INTERLEUKIN 6; MACROPHAGE INHIBITORY PROTEIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; UNCLASSIFIED DRUG; AUTACOID; CCL11 PROTEIN, HUMAN; CCL2 PROTEIN, HUMAN; CCL4 PROTEIN, HUMAN; CCR5 PROTEIN, HUMAN; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; IL6 PROTEIN, HUMAN; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PYRROLE DERIVATIVE;

ADULT; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; LOW DRUG DOSE; MALE; METABOLIC SYNDROME X; MONOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; BLOOD; GENETICS; METABOLISM; MIDDLE AGED;

ADULT; ANTICHOLESTEREMIC AGENTS; C-REACTIVE PROTEIN; CHEMOKINE CCL11; CHEMOKINE CCL2; CHEMOKINE CCL4; CHEMOKINES, CC; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MONOCYTES; PYRROLES; RECEPTORS, CCR5; RNA, MESSENGER;

EID: 84887461604     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12113     Document Type: Article

References (33)

1. Mottillo, S., Filion, K.B., Genest, J., et al,. (2010) The Metabolic Syndrome and Cardiovascular Risk. A Systematic Review and Meta-Analysis. Journal of the American College of Cardiology, 56, 1113-1132.
2. Zeyda, M., &, Stulnig, T.M., (2007) Adipose tissue macrophages. Immunology Letters, 112, 61-67. (Pubitemid 47379852)
3. Woollard, K.J., &, Geissmann, F., (2010) Monocytes in atherosclerosis: subsets and functions. Nature Reviews. Cardiology, 7, 77-86.
4. Patsouris, D., Neels, J.G., Fan, W., et al,. (2009) Glucocorticoids and thiazolidinediones interfere with adipocyte-mediated macrophage chemotaxis and recruitment. Journal of Biological Chemistry, 284, 31223-31235.
5. Lutgens, E., Faber, B., Schapira, K., et al,. (2005) Gene profiling in atherosclerosis reveals a key role for small inducible cytokines: validation using a novel monocyte chemoattractant protein monoclonal antibody. Circulation, 111, 3443-3452. (Pubitemid 40923398)
6. Do, M.S., Jeong, H.S., Choi, B.H., et al,. (2006) Inflammatory gene expression patterns revealed by DNA microarray analysis in TNF-alpha-treated SGBS human adipocytes. Yonsei Medical Journal, 47, 729-736.
7. Kitaura, M., Makajima, T., Imai, T., et al,. (1996) Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor 3. Journal of Biological Chemistry, 271, 7725-7730. (Pubitemid 26107057)
8. Haley, K.J., Lilly, C.M., Yang, J.H., et al,. (2000) Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation, 102, 2185-2189.
9. Martinelli, R., Sabroe, I., LaRosa, G., et al,. (2001) The CC chemokine eotaxin (CCL11) is a partial agonist of CC chemokine receptor 2b. Journal of Biological Chemistry, 276, 42957-42964.
10. Colhoun, H.M., Betteridge, D.J., Durrington, P.N., CARDS investigators et al. (2004) Primary prevention of cardio-vascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 64, 685-696. (Pubitemid 39140624)
11. Ridker, P.M., Danielson, E., Fonseca, F.A., et al,.; JUPITER Study Group (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine, 359, 2195-2207.
12. Ridker, P.M., Cannon, C.P., Morrow, D., et al,. (2005) C-reactive protein levels and outcomes after statin therapy. New England Journal of Medicine, 352, 20-28. (Pubitemid 40075677)
13. Devaraj, S., Chan, E., &, Jialal, I., (2006) Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. Journal of Clinical Endocrinology and Metabolism, 91, 4489-4496. (Pubitemid 44833428)
14. Blanco-Colio, L.M., Martín-Ventura, J.L., de Teresa, E., et al,. (2007) Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. American Heart Journal, 153, 881-888.
15. Singh, U., Devaraj, S., Jialal, I., et al,. (2008) Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. The American Journal of Cardiology, 102, 321-325.
16. Krysiak, R., Gdula-Dymek, A., Bachowski, R., et al,. (2010) Pleiotropic effects of atorvstatin and fenofibrate in metabolic syndrome and different types of pre-diabetes. Diabetes Care, 33, 2266-2270.
17. Cipolletta, C., Ryan, K.E., Hanna, E.V., et al,. (2005) Activation of peripheral blood CD14 monocytes occurs in diabetes. Diabetes, 54, 2779-2786. (Pubitemid 41233602)
18. Rodenburg, R.J., van den Hoogen, F.H., van den Putte, L.B., et al,. (1998) Peripheral blood monocytes of rheumatoid patients do not express elevated TNF alpha, IL-1 beta, and IL-8 mRNA levels: a comparison of monocyte isolation procedures. Journal of Immunological Methods, 221, 169-175. (Pubitemid 29017933)
19. Vasudevan, A.R., Wu, H., Xydakis, A.M., et al,. (2006) Eotaxin and obesity. Journal of Clinical Endocrinology and Metabolism, 91, 256-261. (Pubitemid 43069146)
20. Huber, J., Kiefer, F.W., Zeyda, M., et al,. (2008) CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity. Journal of Clinical Endocrinology and Metabolism, 93, 3215-3221.
21. Maury, E., Ehala-Aleksejev, K., Guiot, Y., et al,. (2007) Adipokines oversecreted by omental adipose tissue in human obesity. Ameican Journal of Physiology. Endocrinology and Metabolism, 293, E656-E665. (Pubitemid 47358976)
22. Hashimoto, I., Wada, J., Hida, A., et al,. (2006) Elevated serum monocyte chemoattractant protein-4 and chronic inflammation in overweight subjects. Obesity, 14, 799-811. (Pubitemid 46219721)
23. Waehre, T., Damas, J.K., Gullestad, L., et al,. (2003) Hydroxymethylglutaryl coenzyme A reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. Journal of the American College of Cardiology, 41, 1460-1467. (Pubitemid 36543360)
24. Tatara, Y., Ohishi, M., Yamamoto, K., et al,. (2009) Macrophage inflammatory protein-1beta induced cell adhesion with increased intracellular reactive oxygen species. Journal of Molecular and Cellular Cardiology, 47, 104-111.
25. Jones, K.L., Maguire, J.J., &, Davenport, A.P., (2011) Chemokine receptor CCR5: from AIDS to atherosclerosis. British Journal of Pharmacology, 162, 1453-1469.
26. Hyde, C.L., MacInnes, A., Sanders, F.A., et al,. (2010) Genetic association of the CCR5 region with lipid levels in at-risk cardiovascular patients. Circulation. Cardiovascular Genetics, 3, 162-168.
27. Cathcart, M.K., (2009) Signal-activated phospholipase regulation of leukocyte chemotaxis. Journal of Lipid Research, 50, S231-S236.
28. Yang, S.J., IglayReger, H.B., Kadouh, H.C., et al,. (2009) Inhibition of the chemokine (C-C motif) ligand 2/chemokine (C-C motif) receptor 2 pathway attenuates hyperglycaemia and inflammation in a mouse model of hepatic steatosis and lipoatrophy. Diabetologia, 52, 972-981.
29. Schwabe, R.F., Bataller, R., &, Brenner, D.A., (2003) Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. American Journal of Physiology. Gastrointestinal and Liver Physiology, 285, 949-958.
30. Ikonomodis, I., Stamatelopoulos, K., Lekakis, J., et al,. (2008) Inflammatory and non-invasive vascular markers: the multimarker approach for risk stratification in coronary artery disease. Atherosclerosis, 199, 3-11.
31. Aquilante, C.L., Kosmiski, L.A., Knutsen, S.D., et al,. (2008) Relationship between plasma resistin concentrations, inflammatory chemokines, and components of the metabolic syndrome in adults. Metabolism: Clinical and Experimental, 57, 494-501. (Pubitemid 351317963)
32. Sathyapalan, T., Kilpatrick, E.S., Coady, A.M., et al,. (2009) The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism, 94, 103-108.
33. Koh, K.K., Quon, M.J., &, Han, S.H., (2010) Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. Journal of the American College of Cardiology, 55, 1209-1216.